title: α-Synuclein fate is determined by USP9X-regulated monoubiquitination.
abstract: α-Synuclein is central to the pathogenesis of Parkinson disease (PD). Mutations as well as accumulation of α-synuclein promote the death of dopaminergic neurons and the formation of Lewy bodies. α-Synuclein is monoubiquitinated by SIAH, but the regulation and roles of monoubiquitination in α-synuclein biology are poorly understood. We now report that the deubiquitinase USP9X interacts in vivo with and deubiquitinates α-synuclein. USP9X levels are significantly lower in cytosolic fractions of PD substantia nigra and Diffuse Lewy Body disease (DLBD) cortices compared to controls. This was associated to lower deubiquitinase activity toward monoubiquitinated α-synuclein in DLBD cortical extracts. A fraction of USP9X seems to be aggregated in PD and DLBD, as USP9X immunoreactivity is detected in Lewy bodies. Knockdown of USP9X expression promotes accumulation of monoubiquitinated α-synuclein species and enhances the formation of toxic α-synuclein inclusions upon proteolytic inhibition. On the other hand, by manipulating USP9X expression levels in the absence of proteolytic impairment, we demonstrate that monoubiquitination controls the partition of α-synuclein between different protein degradation systems. Deubiquitinated α-synuclein is mostly degraded by autophagy, while monoubiquitinated α-synuclein is preferentially degraded by the proteasome. Moreover, monoubiquitination promotes the degradation of α-synuclein, whereas deubiquitination leads to its accumulation, suggesting that the degradation of deubiquitinated α-synuclein by the autophagy pathway is less efficient than the proteasomal one. Lower levels of cytosolic USP9X and deubiquitinase activity in α-synucleinopathies may contribute to the accumulation and aggregation of monoubiquitinated α-synuclein in Lewy bodies. Our data indicate that monoubiquitination is a key determinant of α-synuclein fate.
authors: Department of Pharmacology, The B Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 31096, Israel.
authors: Ruth
authors: R
authors: Rott
authors: Raymonde
authors: R
authors: Szargel
authors: Joseph
authors: J
authors: Haskin
authors: Rina
authors: R
authors: Bandopadhyay
authors: Andrew J
authors: AJ
authors: Lees
authors: Vered
authors: V
authors: Shani
authors: Simone
authors: S
authors: Engelender
mesh_terms: D001343:Autophagy; D045744:Cell Line, Tumor; D002540:Cerebral Cortex / Q000378:metabolism; D059290:Dopaminergic Neurons / Q000378:metabolism; D005786:Gene Expression Regulation; D006801:Humans; D016631:Lewy Bodies / Q000378:metabolism; D020961:Lewy Body Disease / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D059748:Proteolysis; D034741:RNA, Small Interfering / Q000378:metabolism; D025801:Ubiquitin / Q000737:chemistry*; D043222:Ubiquitin Thiolesterase / Q000737:chemistry*; D051844:alpha-Synuclein / Q000737:chemistry*
chemical_list: D034741:RNA, Small Interfering; C506234:USP9X protein, human; D025801:Ubiquitin; D051844:alpha-Synuclein; D043222:Ubiquitin Thiolesterase; D046988:Proteasome Endopeptidase Complex